成功不是最终的，失败不是致命的：晚期肝细胞癌系统治疗的变化

Journal of Cancer Research and Practice Pub Date : 2021-10-01 DOI:10.4103/jcrp.jcrp_21_21

Chiun Hsu

{"title":"成功不是最终的，失败不是致命的：晚期肝细胞癌系统治疗的变化","authors":"Chiun Hsu","doi":"10.4103/jcrp.jcrp_21_21","DOIUrl":null,"url":null,"abstract":"Objective: To review the history of development of systemic therapy for advanced hepatocellular carcinoma (HCC). Data Sources: Published clinical trials of single-agent targeted agents, single-agent immune checkpoint inhibitors (ICI), and ICI-based combination regimens. Results: Key lessons learned from previous positive and negative clinical trials included design of more efficient clinical trials and incorporation of trial endpoints most relevant to clinical benefit. Major challenges included prioritization of novel combination therapies for clinical trials and development of predictive biomarkers. Conclusion: The improved efficacy and safety of systemic therapy will impact on future multi-disciplinary management of HCC through more extensive integration with liver-directed therapy for different stages of HCC patients.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"8 1","pages":"127 - 133"},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma\",\"authors\":\"Chiun Hsu\",\"doi\":\"10.4103/jcrp.jcrp_21_21\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To review the history of development of systemic therapy for advanced hepatocellular carcinoma (HCC). Data Sources: Published clinical trials of single-agent targeted agents, single-agent immune checkpoint inhibitors (ICI), and ICI-based combination regimens. Results: Key lessons learned from previous positive and negative clinical trials included design of more efficient clinical trials and incorporation of trial endpoints most relevant to clinical benefit. Major challenges included prioritization of novel combination therapies for clinical trials and development of predictive biomarkers. Conclusion: The improved efficacy and safety of systemic therapy will impact on future multi-disciplinary management of HCC through more extensive integration with liver-directed therapy for different stages of HCC patients.\",\"PeriodicalId\":31219,\"journal\":{\"name\":\"Journal of Cancer Research and Practice\",\"volume\":\"8 1\",\"pages\":\"127 - 133\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cancer Research and Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcrp.jcrp_21_21\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcrp.jcrp_21_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

摘要

目的:回顾晚期肝细胞癌(HCC)全身治疗的发展历史。数据来源:已发表的单药靶向药物、单药免疫检查点抑制剂(ICI)和基于ICI的联合方案的临床试验。结果:从以往阳性和阴性临床试验中吸取的主要经验教训包括设计更有效的临床试验和纳入与临床获益最相关的试验终点。主要挑战包括为临床试验确定新型联合疗法的优先级和开发预测性生物标志物。结论:全身治疗的疗效和安全性的提高，将通过更广泛地与肝定向治疗相结合，对不同阶段HCC患者的多学科治疗产生影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Success is not final, failure is not fatal: The changing landscape of systemic therapy for advanced hepatocellular carcinoma

Objective: To review the history of development of systemic therapy for advanced hepatocellular carcinoma (HCC). Data Sources: Published clinical trials of single-agent targeted agents, single-agent immune checkpoint inhibitors (ICI), and ICI-based combination regimens. Results: Key lessons learned from previous positive and negative clinical trials included design of more efficient clinical trials and incorporation of trial endpoints most relevant to clinical benefit. Major challenges included prioritization of novel combination therapies for clinical trials and development of predictive biomarkers. Conclusion: The improved efficacy and safety of systemic therapy will impact on future multi-disciplinary management of HCC through more extensive integration with liver-directed therapy for different stages of HCC patients.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Cancer Research and Practice

自引率

0.00%

发文量

审稿时长

24 weeks

期刊介绍： JCRP aims to provide an exchange forum for the cancer researchers and practitioners to publish their timely findings in oncologic disciplines. The scope of the Journal covers basic, translational and clinical research, Cancer Biology, Cancer Immunotherapy, Hemato-oncology, Digestive cancer, Urinary tumor, Germ cell tumor, Breast cancer, Lung cancer, Head and Neck Cancer in a vast range of cancer related topics. The Journal also seeks to enhance and advance the cancer care standards in order to provide cancer patients the best care during the treatments.